Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2016 16:01 ET | Source: Zevra Therapeutics

KemPharm to Present at the Needham & Company’s 15th Annual Healthcare Conference in New York, NY

CORALVILLE, Iowa, April 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
March 28, 2016 16:01 ET | Source: Zevra Therapeutics

KemPharm Receives Clearance from FDA to Initiate Human Clinical Trials of KP511, an Investigational Prodrug of Hydromorphone

CORALVILLE, Iowa, March 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that its Investigational New Drug (IND) application for KP511, KemPharm’s prodrug of...
March 24, 2016 09:09 ET | Source: Zevra Therapeutics

KemPharm Receives NDA User Fee Waiver from FDA

CORALVILLE, Iowa, March 24, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
March 14, 2016 09:58 ET | Source: Zevra Therapeutics

KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP

CORALVILLE, Iowa, March 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug...
March 10, 2016 15:49 ET | Source: Zevra Therapeutics

KemPharm, Inc. Reports Q4 and Year End 2015 Results

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ETRecent Clinical Development & Regulatory Highlights:Submitted New Drug Application (NDA) under Section 505(b)(2) of the...
March 07, 2016 09:40 ET | Source: Zevra Therapeutics

KemPharm Files IND for KP511, an Investigational Prodrug of Hydromorphone

CORALVILLE, Iowa, March 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug...
March 02, 2016 16:05 ET | Source: Zevra Therapeutics

KemPharm, Inc. to Report Fourth Quarter and Year End 2015 Results

CORALVILLE, Iowa, March 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
February 19, 2016 07:30 ET | Source: Zevra Therapeutics

KemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting

CORALVILLE, Iowa, Feb. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced that it will present data from an oral human abuse liability, pharmacokinetic and safety study...
February 18, 2016 07:30 ET | Source: Zevra Therapeutics

KemPharm, Inc. to Present at Upcoming Investor Conferences

CORALVILLE, Iowa, Feb. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
February 10, 2016 07:30 ET | Source: Zevra Therapeutics

FDA Grants Priority Review to KemPharm for KP201/APAP NDA

CORALVILLE, Iowa, Feb. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that the New Drug Application (NDA) for KP201/APAP, its investigational drug candidate for the...